<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wiki.sarg.dev/index.php?action=history&amp;feed=atom&amp;title=CP_55%2C940</id>
	<title>CP 55,940 - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.sarg.dev/index.php?action=history&amp;feed=atom&amp;title=CP_55%2C940"/>
	<link rel="alternate" type="text/html" href="https://wiki.sarg.dev/index.php?title=CP_55,940&amp;action=history"/>
	<updated>2026-06-22T21:31:00Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wiki.sarg.dev/index.php?title=CP_55,940&amp;diff=517416&amp;oldid=prev</id>
		<title>imported&gt;Arthurfragoso: dark mode fix</title>
		<link rel="alternate" type="text/html" href="https://wiki.sarg.dev/index.php?title=CP_55,940&amp;diff=517416&amp;oldid=prev"/>
		<updated>2025-01-11T16:36:06Z</updated>

		<summary type="html">&lt;p&gt;dark mode fix&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{Short description|Chemical compound}}&lt;br /&gt;
{{cs1 config|name-list-style=vanc}}{{Drugbox&lt;br /&gt;
| IUPAC_name = 2-[(1&amp;#039;&amp;#039;R&amp;#039;&amp;#039;,2&amp;#039;&amp;#039;R&amp;#039;&amp;#039;,5&amp;#039;&amp;#039;R&amp;#039;&amp;#039;)-5-Hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol&lt;br /&gt;
| image = CP 55,940-2D-skeletal.svg&lt;br /&gt;
| image_class = skin-invert-image&lt;br /&gt;
| width = 200px&lt;br /&gt;
&amp;lt;!--Clinical data--&amp;gt;&lt;br /&gt;
| tradename =  &lt;br /&gt;
| legal_status =  &lt;br /&gt;
| legal_CA = Schedule II&lt;br /&gt;
| routes_of_administration =  &lt;br /&gt;
&amp;lt;!--Pharmacokinetic data--&amp;gt;&lt;br /&gt;
| metabolism =  &lt;br /&gt;
| elimination_half-life =  &lt;br /&gt;
| excretion =  &lt;br /&gt;
&amp;lt;!--Identifiers--&amp;gt;&lt;br /&gt;
| CAS_number = 83002-04-4&lt;br /&gt;
| UNII_Ref = {{fdacite|correct|FDA}}&lt;br /&gt;
| UNII = KFY70972J5&lt;br /&gt;
| PubChem = 3086156&lt;br /&gt;
| ChEMBL_Ref = {{ebicite|correct|EBI}}&lt;br /&gt;
| ChEMBL = 559612&lt;br /&gt;
|  ChemSpiderID = 94668&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--Chemical data--&amp;gt;&lt;br /&gt;
| C=24 | H=40 | O=3&lt;br /&gt;
|  StdInChI = 1S/C24H40O3/c1-4-5-6-7-14-24(2,3)19-11-13-21(23(27)16-19)22-17-20(26)12-10-18(22)9-8-15-25/h11,13,16,18,20,22,25-27H,4-10,12,14-15,17H2,1-3H3/t18-,20-,22-/m1/s1&lt;br /&gt;
|  StdInChIKey = YNZFFALZMRAPHQ-SYYKKAFVSA-N&lt;br /&gt;
| smiles = O[C@H]1C[C@@H](C2=CC=C(C(C)(C)CCCCCC)C=C2O)[C@H](CCCO)CC1&lt;br /&gt;
}}&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;&amp;lt;span lang=&amp;quot;he&amp;quot;&amp;gt;CP&amp;lt;/span&amp;gt; 55,940&amp;#039;&amp;#039;&amp;#039; is a [[synthetic cannabinoid]] which mimics the effects of naturally occurring [[Tetrahydrocannabinol|THC]] (one of the psychoactive compounds found in [[cannabis]]). CP 55,940 was created by [[Pfizer]] in 1974 but was never marketed. It is currently used as a research tool to study the [[endocannabinoid system]].&amp;lt;ref&amp;gt;{{cite journal | vauthors = Glass M, Dragunow M, Faull RL | title = Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain | journal = Neuroscience | volume = 77 | issue = 2 | pages = 299–318 | date = March 1997 | pmid = 9472392 | doi = 10.1016/s0306-4522(96)00428-9 | s2cid = 40213209 }}&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Pharmacology ==&lt;br /&gt;
&lt;br /&gt;
CP 55,940 is 45 times more potent than Δ&amp;lt;sup&amp;gt;9&amp;lt;/sup&amp;gt;-THC, and fully antagonized by [[rimonabant]] (SR141716A).&amp;lt;ref&amp;gt;{{cite journal | vauthors = Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A, Brelière JC, Soubrié P, Le Fur G | display-authors = 6 | title = Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain | journal = Life Sciences | volume = 58 | issue = 15 | pages = 1239–47 | year = 1996 | pmid = 8614277 | doi = 10.1016/0024-3205(96)00085-9 }}&amp;lt;/ref&amp;gt; It is considered a full agonist at both CB&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt; and CB&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt; receptors and has [[Disassociation constant#Protein-ligand binding|K&amp;lt;sub&amp;gt;i&amp;lt;/sub&amp;gt;]] values of 0.58&amp;amp;nbsp;nM and 0.68&amp;amp;nbsp;nM respectively, but is an antagonist at [[GPR55]], the putative &amp;quot;CB&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;&amp;quot; receptor.&amp;lt;ref&amp;gt;{{cite journal | vauthors = Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME | title = Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands | journal = The Journal of Biological Chemistry | volume = 284 | issue = 43 | pages = 29817–27 | date = October 2009 | pmid = 19723626 | pmc = 2785612 | doi = 10.1074/jbc.M109.050187 | doi-access = free }}&amp;lt;/ref&amp;gt; CP 55,940 binding has been detected in the cytosol of rat brain cerebral cortex.&amp;lt;ref&amp;gt;{{cite journal | vauthors = Qureshi J, Saady M, Cardounel A, Kalimi M | title = Identification and characterization of a novel synthetic cannabinoid CP 55,940 binder in rat brain cytosol | journal = Molecular and Cellular Biochemistry | volume = 181 | issue = 1–2 | pages = 21–27 | date = April 1998 | pmid = 9562238 | doi = 10.1023/A:1006855504094 | s2cid = 6200670 }}&amp;lt;/ref&amp;gt; It can upregulate [[5-HT2A receptor|5-HT&amp;lt;sub&amp;gt;2A&amp;lt;/sub&amp;gt;]] receptors in mice.&amp;lt;ref&amp;gt;{{cite journal | vauthors = Franklin JM, Carrasco GA | title = Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling | journal = Synapse | volume = 67 | issue = 3 | pages = 145–59 | date = March 2013 | pmid = 23151877 | pmc = 3552103 | doi = 10.1002/syn.21626 }}&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== In vitro studies ==&lt;br /&gt;
&lt;br /&gt;
CP 55,940 induced cell death in NG 108-15 Mouse neuroblastoma x Rat glioma hybrid brain cancer (genetically engineered mouse x rat brain cancer) cells.&amp;lt;ref&amp;gt;{{cite journal | vauthors = Tomiyama K, Funada M | title = Cytotoxicity of synthetic cannabinoids found in &amp;quot;Spice&amp;quot; products: the role of cannabinoid receptors and the caspase cascade in the NG 108-15 cell line | journal = Toxicology Letters | volume = 207 | issue = 1 | pages = 12–7 | date = November 2011 | pmid = 21907772 | doi = 10.1016/j.toxlet.2011.08.021 }}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{ cite web | url = http://www.hpacultures.org.uk/products/celllines/generalcell/detail.jsp?refId=88112302&amp;amp;collection=ecacc_gc | title = General Cell Collection: NG108-15 | publisher = Public Health England Culture Collections }}&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== In vivo studies ==&lt;br /&gt;
&lt;br /&gt;
CP 55,940 showed protective effects on rat brain mitochondria upon paraquat exposure.&amp;lt;ref&amp;gt;{{cite journal | vauthors = Velez-Pardo C, Jimenez-Del-Rio M, Lores-Arnaiz S, Bustamante J | title = Protective effects of the synthetic cannabinoids CP55,940 and JWH-015 on rat brain mitochondria upon paraquat exposure | journal = Neurochemical Research | volume = 35 | issue = 9 | pages = 1323–32 | date = September 2010 | pmid = 20514518 | doi = 10.1007/s11064-010-0188-1 | hdl-access = free | hdl = 11336/67604 | s2cid = 821457 }}&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
It also showed neuroprotective effects by reducing intracellular calcium release and reducing hippocampal cell death in cultured neurons subjected to high levels of [[NMDA]].&amp;lt;ref&amp;gt;{{cite journal | vauthors = Zhuang SY, Bridges D, Grigorenko E, McCloud S, Boon A, Hampson RE, Deadwyler SA | title = Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores | journal = Neuropharmacology | volume = 48 | issue = 8 | pages = 1086–96 | date = June 2005 | pmid = 15910885 | doi = 10.1016/j.neuropharm.2005.01.005 | s2cid = 14953725 }}&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== See also ==&lt;br /&gt;
* [[CP 42,096]]&lt;br /&gt;
* [[CP 47,497]]&lt;br /&gt;
* [[CP 55,244]]&lt;br /&gt;
* [[Cycloheptyl CP 55,940]]&lt;br /&gt;
&lt;br /&gt;
== References ==&lt;br /&gt;
{{reflist}}&lt;br /&gt;
&lt;br /&gt;
{{Cannabinoids}}&lt;br /&gt;
{{Hallucinogens}}&lt;br /&gt;
{{Cannabinoidergics}}&lt;br /&gt;
&lt;br /&gt;
[[Category:Primary alcohols]]&lt;br /&gt;
[[Category:Cyclohexanols]]&lt;br /&gt;
[[Category:Cannabinoids]]&lt;br /&gt;
[[Category:Designer drugs]]&lt;br /&gt;
[[Category:Drugs developed by Pfizer]]&lt;br /&gt;
[[Category:Phenols]]&lt;br /&gt;
[[Category:CB1 receptor agonists]]&lt;br /&gt;
[[Category:CB2 receptor agonists]]&lt;/div&gt;</summary>
		<author><name>imported&gt;Arthurfragoso</name></author>
	</entry>
</feed>